Abemaciclib for Thyroid Cancer

Overseen by Saad A Khan, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Stanford University

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid

Research Team

Saad A Khan, MD

Principal Investigator

Stanford Universiy

Eligibility Criteria

This trial is for adults with advanced anaplastic or undifferentiated thyroid cancer that can't be cured by surgery or radiation. Participants must have acceptable organ function, not be pregnant, and agree to use contraception. They should not have other serious medical conditions, a history of certain heart issues, or active infections.

Inclusion Criteria

I have had my airway checked for blockages due to a large thyroid or neck mass.

Have measurable disease based on RECIST 1.1

I agree to provide a recent biopsy of my tumor.

Exclusion Criteria

I do not have any ongoing serious infections.

Patients with known hypersensitivity to any of the excipients of abemaciclib

I am not pregnant or breastfeeding.

Treatment Details

Interventions

• Abemaciclib (CDK4/6 Inhibitor)

Trial Overview The study tests the effectiveness of abemaciclib in treating advanced thyroid cancer. Patients will take this oral medication and their response to treatment will be monitored according to specific health criteria outlined in the study design.

Participant Groups

Group I: Abemaciclib Experimental Treatment 1 Intervention

Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+

Dr. Richard A. Miller

Stanford University

Chief Executive Officer since 2023

Stanford University, MD

Dr. Robert Schott

Stanford University

Chief Medical Officer since 2021

University of Michigan, MD